Gene therapy's door opens younger: UK clears the first CRISPR treatment for children from age five

Britain's medicines regulator, the MHRA, has extended its approval of Casgevy — the world's first CRISPR gene therapy — to children as young as five with severe sickle cell disease or transfusion-dependent beta-thalassemia, lowering the UK age threshold from twelve. The one-time treatment edits a patient's own blood stem cells so their body can make healthy haemoglobin again. One honest caveat matters: regulatory clearance is not the same as NHS availability. For the newly eligible five-to-eleven group, a NICE assessment and a funding agreement still lie ahead before the NHS can offer it — for older patients that process took fourteen months. The door is now legally open; making it walk-through-able is the next job.

SDG 3 · Good health and well-being — Mechanism: policy reform